Latest From Scrip Team
Pipeline Watch: 18 New Approvals Plus 14 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move Renovacor Clover Biopharmaceuticals and More
Recent executive moves in the industry include C-suite changes at Renovacor and Acer Therapeutics. Meanwhile, new directors were appointed at Clover Pharmaceuticals and Chemomab Therapeutics, among others.
Pipeline Watch: Phase III EHA Trial Updates And Nine Approvals
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
BIO 2022 Notebook: Future Directions For R&D
News and views from day four of the BIO annual meeting include a fireside chat with FDA commissioner Robert Califf, gene therapy insights, and pharma efforts to provide cancer medicines in lower income countries.
Executives On The Move: CRISPr Therapeutics, Syndax Pharmaceuticals and More
Recent executive changes in the industry include C-suite changes at Sundax Pharmaceuticals and NRx Pharmaceuticals. Meanwhile, new directors were appointed at Verve Therapeutics and CRISPr Therapeutics, among others.